{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:00:57Z","timestamp":1775242857284,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s12282-024-01656-5","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T08:23:17Z","timestamp":1733300597000},"page":"314-328","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A 5-year review of genomic medicine in breast cancer: insights from C-CAT data on 3776 Japanese patients"],"prefix":"10.1007","volume":"32","author":[{"given":"Midori","family":"Morita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Tsunashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuhiro","family":"Yoshinami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Iwasaku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sae","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikage","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6090-0137","authenticated-orcid":false,"given":"Yasuto","family":"Naoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"key":"1656_CR1","unstructured":"C-CAT registration status. Available from: https:\/\/for-patients.c-cat.ncc.go.jp\/registration_status\/. [accessed on]"},{"issue":"11","key":"1656_CR2","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1158\/2159-8290.CD-22-0417","volume":"12","author":"T Kohno","year":"2022","unstructured":"Kohno T, Kato M, Kohsaka S, Sudo T, Tamai I, Shiraishi Y, et al. C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan. Cancer Discov. 2022;12(11):2509\u201315. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0417.","journal-title":"Cancer Discov"},{"issue":"1","key":"1656_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/jalm\/jfad091","volume":"9","author":"MY Tjota","year":"2024","unstructured":"Tjota MY, Segal JP, Wang P. Clinical utility and benefits of comprehensive genomic profiling in cancer. J Appl Lab Med. 2024;9(1):76\u201391. https:\/\/doi.org\/10.1093\/jalm\/jfad091.","journal-title":"J Appl Lab Med"},{"issue":"4","key":"1656_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102981","volume":"9","author":"T Kubo","year":"2024","unstructured":"Kubo T, Sunami K, Koyama T, Kitami M, Fujiwara Y, Kondo S, et al. The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology. ESMO Open. 2024;9(4): 102981. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102981.","journal-title":"ESMO Open"},{"issue":"4","key":"1656_CR5","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1111\/cas.13969","volume":"110","author":"K Sunami","year":"2019","unstructured":"Sunami K, Ichikawa H, Kubo T, Kato M, Fujiwara Y, Shimomura A, et al. Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study. Cancer Sci. 2019;110(4):1480\u201390. https:\/\/doi.org\/10.1111\/cas.13969.","journal-title":"Cancer Sci"},{"issue":"12","key":"1656_CR6","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1111\/cas.15993","volume":"114","author":"I Fukada","year":"2023","unstructured":"Fukada I, Mori S, Hayashi N, Hosonaga M, Xiaofei W, Yamazaki M, et al. Prognostic impact of cancer genomic profile testing for advanced or metastatic solid tumors in clinical practice. Cancer Sci. 2023;114(12):4632\u201342. https:\/\/doi.org\/10.1111\/cas.15993.","journal-title":"Cancer Sci"},{"issue":"11","key":"1656_CR7","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1111\/cas.15517","volume":"113","author":"K Sunami","year":"2022","unstructured":"Sunami K, Naito Y, Komine K, Amano T, Ennishi D, Imai M, et al. Chronological improvement in precision oncology implementation in Japan. Cancer Sci. 2022;113(11):3995\u20134000. https:\/\/doi.org\/10.1111\/cas.15517.","journal-title":"Cancer Sci"},{"issue":"13","key":"1656_CR8","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","volume":"16","author":"C Le Tourneau","year":"2015","unstructured":"Le Tourneau C, Delord JP, Gon\u00e7alves A, Gavoille C, Dubot C, Isambert N, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16(13):1324\u201334. https:\/\/doi.org\/10.1016\/S1470-2045(15)00188-6.","journal-title":"Lancet Oncol"},{"issue":"7","key":"1656_CR9","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1111\/cas.15826","volume":"114","author":"M Ikegami","year":"2023","unstructured":"Ikegami M. Prognostic benefit of comprehensive genomic profiling in clinical practice remains uncertain. Cancer Sci. 2023;114(7):3053\u20135. https:\/\/doi.org\/10.1111\/cas.15826.","journal-title":"Cancer Sci"},{"issue":"22","key":"1656_CR10","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1200\/JCO.20.02923","volume":"39","author":"AS Alva","year":"2021","unstructured":"Alva AS, Mangat PK, Garrett-Mayer E, Halabi S, Hansra D, Calfa CJ, et al. Pembrolizumab in patients with metastatic breast cancer with high tumor mutational burden: Results from the targeted agent and Profiling Utilization Registry (TAPUR) Study. J Clin Oncol. 2021;39(22):2443\u201351. https:\/\/doi.org\/10.1200\/JCO.20.02923.","journal-title":"J Clin Oncol"},{"issue":"17","key":"1656_CR11","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jama.2024.2396","volume":"331","author":"ITT Liu","year":"2024","unstructured":"Liu ITT, Kesselheim AS, Cliff ERS. Clinical benefit and regulatory outcomes of cancer drugs receiving accelerated approval. JAMA. 2024;331(17):1471\u20139. https:\/\/doi.org\/10.1001\/jama.2024.2396.","journal-title":"JAMA"},{"issue":"3","key":"1656_CR12","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/annonc\/mdv611","volume":"27","author":"N Niikura","year":"2016","unstructured":"Niikura N, Tomotaki A, Miyata H, Iwamoto T, Kawai M, Anan K, et al. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry. Ann Oncol. 2016;27(3):480\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdv611.","journal-title":"Ann Oncol"},{"issue":"22","key":"1656_CR13","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388(22):2058\u201370. https:\/\/doi.org\/10.1056\/NEJMoa2214131.","journal-title":"N Engl J Med"},{"issue":"12","key":"1656_CR14","doi-asserted-by":"publisher","first-page":"4300","DOI":"10.1111\/cas.15586","volume":"113","author":"H Ida","year":"2022","unstructured":"Ida H, Koyama T, Mizuno T, Sunami K, Kubo T, Sudo K, et al. Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice. Cancer Sci. 2022;113(12):4300\u201310. https:\/\/doi.org\/10.1111\/cas.15586.","journal-title":"Cancer Sci"},{"issue":"5","key":"1656_CR15","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1111\/cas.16130","volume":"115","author":"M Ishida","year":"2024","unstructured":"Ishida M, Iwasaku M, Doi T, Ishikawa T, Tachibana Y, Sawada R, et al. Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non-small cell lung cancer. Cancer Sci. 2024;115(5):1656\u201364. https:\/\/doi.org\/10.1111\/cas.16130.","journal-title":"Cancer Sci"},{"issue":"5","key":"1656_CR16","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1158\/2159-8290","volume":"14","author":"S Horie","year":"2024","unstructured":"Horie S, Saito Y, Kogure Y, Mizuno K, Ito Y, Tabata M, et al. Pan-cancer comparative and integrative analyses of driver alterations using Japanese and International Genomic Databases. Cancer Discov. 2024;14(5):786\u2013803. https:\/\/doi.org\/10.1158\/2159-8290.","journal-title":"Cancer Discov"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-024-01656-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-024-01656-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-024-01656-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T08:05:50Z","timestamp":1740038750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-024-01656-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1656"],"URL":"https:\/\/doi.org\/10.1007\/s12282-024-01656-5","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,4]]},"assertion":[{"value":"15 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Koichi Takayama received grants from Chugai Pharmaceutical and Ono Pharmaceutical, and personal fees from AstraZeneca, Chugai Pharmaceutical, MSD, Eli Lilly, Boehringer Ingelheim, and Daiichi Sankyo. Yasuto Naoi has received research funding from Sysmex, ONO, Daiichi-Sankyo and AstraZeneca, and honoraria from AstraZeneca, Pfizer, Eli Lilly, ONO, Daiichi-Sankyo and Chugai outside the submitted work; he holds joint patents with Sysmex including Curebest\u2122 95GC Breast (JP.5725274.B2). The other authors declare that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval of the research protocol by the Ethics Review Committee of Kyoto Prefectural University of Medicine (ERB-C-2860) and by the review board of C-CAT (CDU2023-025N).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}